AKT1 and glioblastoma: Alongside RBP-targeting, the heparanase inhibitor RDS3337 may further enhance efficacy against VM by targeting VM-associated pathways such as MMP and PI3K/Akt pathways, and serve as a complementary method for VM suppression in GBM [133,134].